Personalis (NASDAQ:PSNL) Hits New 12-Month High – Should You Buy?

Personalis, Inc. (NASDAQ:PSNL) shares hit a new 52-week high on Thursday . The company traded as high as $12.74 and last traded at $12.7180, with a volume of 1213241 shares traded. The stock had previously closed at $11.36.

Analyst Upgrades and Downgrades

A number of research firms recently issued reports on PSNL. Morgan Stanley reduced their target price on Personalis from $10.00 to $9.00 and set an “equal weight” rating on the stock in a research note on Tuesday, May 12th. Needham & Company LLC increased their price objective on Personalis from $10.00 to $12.00 and gave the company a “buy” rating in a research note on Friday, February 27th. Weiss Ratings restated a “sell (d-)” rating on shares of Personalis in a report on Tuesday, April 21st. Wall Street Zen cut shares of Personalis from a “hold” rating to a “sell” rating in a research note on Saturday, June 13th. Finally, BTIG Research cut their price objective on shares of Personalis from $13.00 to $11.00 and set a “buy” rating for the company in a research report on Monday, May 11th. Five research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, Personalis has an average rating of “Moderate Buy” and an average price target of $11.00.

Personalis Stock Performance

The company’s fifty day moving average price is $8.17 and its two-hundred day moving average price is $8.23. The firm has a market capitalization of $1.31 billion, a PE ratio of -12.30 and a beta of 2.28.

Personalis (NASDAQ:PSNL) last issued its quarterly earnings results on Thursday, May 7th. The company reported ($0.29) EPS for the quarter, missing the consensus estimate of ($0.23) by ($0.06). The company had revenue of $15.47 million for the quarter, compared to analyst estimates of $14.48 million. Personalis had a negative return on equity of 43.52% and a negative net margin of 148.11%. On average, equities analysts expect that Personalis, Inc. will post -1.06 earnings per share for the current year.

Insiders Place Their Bets

In related news, CEO Christopher M. Hall sold 80,091 shares of the stock in a transaction on Friday, May 29th. The stock was sold at an average price of $11.02, for a total value of $882,602.82. Following the transaction, the chief executive officer directly owned 235,986 shares of the company’s stock, valued at approximately $2,600,565.72. This trade represents a 25.34% decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CFO Aaron Tachibana sold 40,000 shares of Personalis stock in a transaction on Thursday, June 4th. The shares were sold at an average price of $12.01, for a total value of $480,400.00. Following the completion of the transaction, the chief financial officer owned 198,833 shares in the company, valued at $2,387,984.33. The trade was a 16.75% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last 90 days, insiders have sold 178,799 shares of company stock valued at $2,031,692. Insiders own 4.20% of the company’s stock.

Institutional Investors Weigh In On Personalis

Several institutional investors and hedge funds have recently modified their holdings of PSNL. Bank of America Corp DE raised its holdings in shares of Personalis by 85.4% during the 1st quarter. Bank of America Corp DE now owns 111,306 shares of the company’s stock valued at $709,000 after buying an additional 51,273 shares during the period. Janus Henderson Group PLC acquired a new position in shares of Personalis during the first quarter worth $192,000. ADAR1 Capital Management LLC purchased a new position in shares of Personalis in the first quarter valued at $159,000. Sei Investments Co. grew its holdings in Personalis by 148.3% during the 1st quarter. Sei Investments Co. now owns 139,046 shares of the company’s stock valued at $886,000 after purchasing an additional 83,040 shares in the last quarter. Finally, Dimensional Fund Advisors LP lifted its holdings in Personalis by 8.4% in the 1st quarter. Dimensional Fund Advisors LP now owns 1,066,248 shares of the company’s stock worth $6,791,000 after buying an additional 83,074 shares in the last quarter. Hedge funds and other institutional investors own 61.91% of the company’s stock.

About Personalis

Personalis, Inc (NASDAQ: PSNL) is a clinical‐stage genomics company that develops and markets advanced next‐generation sequencing (NGS) services and assays designed to accelerate precision medicine. The Company’s core offering is the ImmunoID NeXT™ Platform, which combines comprehensive tumor profiling—including whole exome, transcriptome, and T‐cell receptor sequencing—with proprietary bioinformatics to identify biomarkers and guide immuno‐oncology research. Personalis serves biopharmaceutical companies, academic institutions, and clinical research organizations seeking in‐depth insights into cancer, autoimmune diseases and other complex conditions.

In addition to its flagship ImmunoID NeXT™ Platform, Personalis offers a suite of customizable sequencing assays for biomarker discovery, clinical trial support and companion diagnostic development.